• Species Reactivity

  Human, Mouse

• Specificity

  Detect human and mouse Tenascin C in Western blots.

• Source

  Monoclonal Rat IgG    _2A Clone # 578

• Purification

  Protein A or G purified from hybridoma culture supernatant

• Immunogen

  Mouse immature astrocyte-derived Tenascin C

• Formulation

  Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.

• Endotoxin Level

  <0.10 EU per 1 μg of the antibody by the LAL method.  

• Label

  Unconjugated

Applications

• Recommended    
  Concentration

  Sample

• Western Blot

  Morganti, M.     et al. (1990) Exp. Neurol.     109:98.

• 
  

• Immunocytochemistry

  8-25 µg/mL

  See below

• 
  

• Neutralization

  Husmann, K.     et al. (1992) J. Cell Biol.     116:1475.

Please Note: Optimal dilutions should be determined by each laboratory for each application.  are available in the Technical Information section on our website.

Data Examples

Preparation and Storage

• Reconstitution

  Reconstitute at 0.5 mg/mL in sterile PBS.

• Shipping

  The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

• Stability & Storage

  Use a manual defrost freezer and avoid repeated freeze-thaw cycles.    

• 12 months from date of receipt, -20 to -70 °C as supplied.

• 1 month, 2 to 8 °C under sterile conditions after reconstitution.

• 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Tenascin C

Tenascin C, also known as hexabrachion, cytotactin, neuronectin, GMEM, JI, myotendinous antigen, glioma-associated-extracellular matrix antigen, and GP 150‑225, is a member of the Tenascin family of extracellular matrix proteins. It is secreted as a disulfide-linked homohexamer whose subunits can vary in size from approximately 200 kDa to over 300 kDa due to differences in glycosylation (1). Rotary-shadowed electron micrographs of the purified molecule show six strands joined to one another at one end in a globular domain with each arm terminating in a knob-like structure (2, 3). The human Tenascin C monomer is synthesized as a precursor with a 22 amino acid (aa) signal sequence and a 2179 aa mature chain. The mature chain consists of a coiled-coil region (aa 118‑145), followed by
15 EGF‑like domains, 15 fibronectin type-III domains, and a fibrinogen C-terminal domain. In addition, there are 23 potential sites of N‑linked glycosylation. Alternative splicing within the fibronectin type-III repeats produces six isoforms for human Tenascin C. Mature human Tenascin C (isoform 1) shares 84% aa sequence identity with mature mouse Tenascin C. In the developing embryo, Tenascin C is expressed during neural, skeletal, and vascular morphogenesis (1, 2). In the adult, it virtually disappears with continued basal expression detectable only in tendon-associated tissues (1, 2). However, great up-regulation in expression occurs in tissues undergoing remodeling processes seen during wound repair and neovascularization or in pathological states such as inflammation or tumorigenesis (1, 4, 5). Biologically, Tenascin C functions as an adhesion-modulatory extracellular matrix protein (1, 4‑8). Specifically, it antagonizes the adhesive effects of fibronectin, and impacts the ability of fibroblasts to deposit and contract the matrix by affecting the morphology and signaling pathways of adherent cells (5‑7). Tenascin C acts by blocking syndecan-4 binding at the edges of the wound and by suppressing fibronectin-mediated activation of RhoA and focal adhesion kinase (FAK) (4‑8). Tenascin C thus promotes epidermal cell migration and proliferation during wound repair.

• References:

1. Hsia, H.C. and J.E. Schwarzbauer (2005) J. Biol. Chem. 280:26641.

2. Nies, D.E. et al. (1991) J. Biol. Chem. 266:2818.

3. Erickson, H.P and J.L. Iglesias (1984) Nature 311:267.

4. Orend, G. et al. (2003) Oncogene 22:3917.

5. Wenk, M.B. et al. (2000) J. Cell Biol. 150:913.

6. Midwood, K.S. et al. (2004) Mol. Biol. Cell 15:5670.

7. Midwood, K.S. and J. E. Schwarzbauer (2002) Mol. Biol. Cell 13:3601.

8. Hsia, H.C. and J.E. Schwarzbauer (2006) J. Surg. Res. 136:92.

• Entrez Gene IDs:

  3371 (Human); 21923 (Mouse); 116640 (Rat)

• Alternate Names:

  150-225; Cytotactin; Glioma-associated-extracellular matrix antigen; GMEM; GP 150-225; hexabrachion (tenascin C, cytotactin); hexabrachion (tenascin); Hexabrachion; HXB; HXBcytotactin; JI; MGC167029; Myotendinous antigen; neuronectin; Tenascin C; Tenascin J1; tenascin; tenascin-C isoform 14/AD1/16; Tenascin-C; TNC; TN-C; TNGP